A Phase II Clinical Study to Evaluate the Efficacy and Safety of HLX43 (Anti-PD-L1 ADC) in Patients With Advanced Gynecological Malignant Tumors

A Phase II Clinical Study to Evaluate the Efficacy and Safety of HLX43 (Anti-PD-L1 ADC) in Patients With Advanced Gynecological Malignant Tumors is a phase 2 interventional study registered as NCT06769152 by Shanghai Henlius Biotech, with 190 participants planned, started 2025-02-20 and due to reach its primary completion in 2026-12-31. Interventions recorded: HLX43. Conditions listed: Cervical Cancer, Ovarian Cancer. No results are recorded here; the registry entry is the source.